YektaSonics Inc.
YektaSonics Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at YektaSonics Inc..
YektaSonics Inc. is a company.
Key people at YektaSonics Inc..
Key people at YektaSonics Inc..
YektaSonics Inc. develops cost-effective ultrasound beamformers and electronic systems, including phased arrays and power modules, that drive transducers to generate acoustic waves with precise phase and power control for medical and non-medical applications.[1][3][4] The company primarily serves the Focused Ultrasound (FUS) sector, enabling non-invasive treatments for over 180 conditions in oncology, gynecology, neurology, psychiatry, and more, while also addressing engineering uses like fault detection and flow control; its innovations reduce costs and improve performance, positioning it for growth in therapeutics like the ultrasonic Deep Brain Stimulator (uDBS).[1][2][4][5]
With under 25 employees and revenue below $5 million, YektaSonics operates from Richmond, California (with ties to Santa Cruz), focusing on patented electronics that eliminate matching networks, produce harmonic-free outputs, and enable miniaturization.[1][2][3]
Founded in 2017, YektaSonics emerged from expertise in ultrasound technology, led by founder Navid (likely Navid Khodapanah), with advisor Ali Niknejad from UC Berkeley providing guidance on the patented phased array systems.[3][5] The idea stemmed from breakthroughs in low-cost, high-power FUS drivers, building on National Science Foundation (NSF) Phase I funding and university ties, including UC collaborations, to advance non-invasive alternatives to invasive procedures like Deep Brain Stimulation (DBS).[4][5]
Early traction included developing scalable, miniaturized electronics for FUS devices, forging relationships in medical and industry communities, and planning uDBS prototypes to treat neurological conditions like epilepsy and Parkinson's without surgery.[2][5]
YektaSonics rides the Focused Ultrasound revolution, akin to MRI's impact on diagnostics 40 years ago, by enabling non-invasive therapeutics amid rising demand for surgery-free treatments in neurology and oncology.[4][5] Timing aligns with only 9 FDA-approved FUS indications despite 180+ potentials, fueled by market forces like aging populations needing alternatives to chemotherapy/DBS and cost pressures in medtech.[1][2]
It influences the ecosystem by democratizing FUS access through cheaper electronics, accelerating adoption in startups and hospitals, and bridging hardware with therapeutics via university/NSF ties.[5]
YektaSonics is primed to launch uDBS and expand phased arrays, capitalizing on FUS growth as approvals multiply and miniaturization enables portable devices.[2][4][5] Trends like AI-enhanced beamforming and non-invasive neurotech will amplify its edge, potentially evolving it from niche innovator to key enabler in a multi-billion medtech market. Watch for partnerships or funding to scale production, solidifying its role in "curing with sound."[4][5]
